Business
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass., August 13, 2025--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC).
About this update from Vedanta Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":855,"height":214,"url":"https://media.zenfs.com/en/business-wire.com/48abca149e788801fd6843a347a212fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BEbzhL5coFyrTMIYE5Bttg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/48abca149e788801fd6843a347a212fb","width":855,"height":214},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/X1E_S80SlOkjHHimJ_T8hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3MTA7aD00Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/48abca149e788801fd6843a347a212fb","width":855,"height":214}},"lazy":false},{"type":"text","content":"VE202 was well tolerated, with no reports of treatment-related serious adverse events","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"Vedanta to focus resources on ongoing Phase 3 RESTORATiVE303 registrational study of VE303 in recurrent Clostridioides difficile infection","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., August 13, 2025--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that its candidate VE202 did not meet the primary endpoint of endoscopic response in the Phase 2 COLLECTiVE202 study for the treatment of patients with mild-to-moderate ulcerative colitis (UC).","length":404,"tagName":"p"},{"type":"text","content":""We are very disappointed that our study did not meet its efficacy endpoints, and our greatest regret is that people living with inflammatory bowel disease will not, for now, have the opportunity to benefit from a new treatment option," said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. "The gut microbiome is a well-recognized driver of IBD, yet remains a facet of the disease untouched by current treatments. As a field, we have not yet succeeded in making a meaningful impact for people with IBD through microbiome-based approaches, but every study moves us closer to that goal. We are committed to sharing further ana...